Denizar Vianna Araújo

Denizar Vianna Araújo

Auto-generated profile, based on publicly available information

Denizar Vianna Araújo

Universidade do Estado do Rio de Janeiro, Brazil

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2012 in BMC Public Health
Verified
Journal Article
Open access
PDF file
LBLUCIANA BAHIA
LUCIANA BAHIA
ECEvandro Silva Freire Coutinho
Evandro Silva Freire Coutinho
LBLaura Augusta Barufaldi
Laura Augusta Barufaldi
GAGabriela de Azevedo Abreu
Gabriela de Azevedo Abreu
TMThainá Alves Malhão
Thainá Alves Malhão
DADenizar Vianna Araujo
Denizar Vianna Araujo
Obesity is a major global epidemic and a burden to society and health systems. It is well known risk factor for a number of chronic medical conditions with high morbidity and mortality. This study aimed to provide an estimate of the direct costs associated to outpatient and inpatient care of overweight and obesity related diseases in the perspective of the Brazilian Health System (SUS).

31 July 2020 in PharmacoEconomics
Verified
Journal Article
Closed access
PDF file
CDCarolina Zampirolli Dias
Carolina Zampirolli Dias
BGBrian Godman
Brian Godman
LGLudmila Peres Gargano
Ludmila Peres Gargano
PAPâmela Santos Azevedo
Pâmela Santos Azevedo
MGMarina Morgado Garcia
Marina Morgado Garcia
AJAugusto Afonso Guerra Junior
Augusto Afonso Guerra Junior

MMICHELLE ROSA
MICHELLE ROSA
RRRoger Rosa
Roger Rosa
MCMarcelo G. Correia
Marcelo G. Correia
DADenizar V. Araujo
Denizar V. Araujo
LBLUCIANA BAHIA
LUCIANA BAHIA
CTCristiana M Toscano
Cristiana M Toscano
Diabetes is associated with a significant burden globally. The costs of diabetes-related hospitalizations are unknown in most developing countries. The aim of this study was to estimate the total number and economic burden of hospitalizations attributable to diabetes mellitus (DM) and its complications in adults from the perspective of the Brazilian Public Health System in 2014. Data sources included the National Health Survey (NHS) and National database of Hospitalizations (SIH). We considered diabetes, its microvascular (retinopathy, nephropathy, and neuropathy) and macrovascular complications (coronary heart disease, cerebrovascular disease, and peripheral arterial disease), respiratory and urinary tract infections, as well as selected cancers. Assuming that DM patients are hospitalized for these conditions more frequently that non-DM individuals, we estimated the etiological fraction of each condition related to DM, using the attributable risk methodology. We present number, average cost per case, and overall costs of hospitalizations attributable to DM in Brazil in 2014, stratified by condition, state of the country, gender and age group. In 2014, a total of 313,273 hospitalizations due to diabetes in adults were reported in Brazil (4.6% of total adult hospitalization), totaling (international dollar) Int$264.9 million. The average cost of an adult hospitalization due to diabetes was Int$845, 19% higher than hospitalization without DM. Hospitalizations due to cardiovascular diseases related to diabetes accounted for the higher proportion of costs (47.9%), followed by microvascular complications (25.4%) and DM per se (18.1%). Understanding the costs of diabetes and its major complications is crucial to raise awareness and to support the decision-making process on policy implementation, also allowing the assessment of prevention and control strategies.

2 July 2019 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
LBLUCIANA BAHIA
LUCIANA BAHIA
MMICHELLE ROSA
MICHELLE ROSA
DADenizar Vianna Araujo
Denizar Vianna Araujo
MCMarcelo Goulart Correia
Marcelo Goulart Correia
RRRoger Rosa
Roger Rosa
CTCristiana M Toscano
Cristiana M Toscano
Diabetes and its complications produce significant clinical, economic and social impact. The knowledge of the costs of diabetes generates subsidies to maintain the financial sustainability of public health and social security systems, guiding research and health care priorities. The aim of this study was to estimate the economic burden of diabetes in Brazilian adults in 2014, considering the perspectives of the public health care system and the society. A prevalence-based approach was used to estimate the annual health resource utilization and costs attributable to diabetes and related conditions. The healthcare system perspective considered direct medical costs related to outpatient and hospitalization costs. The societal perspective considered non-medical (transportation and dietary products) and indirect costs (productivity loss, disability, and premature retirement). Outpatient costs included medicines, health professional visits, exams, home glucose monitoring, ophthalmic procedures, and costs related to end stage renal disease. The costs of hospitalization attributed to diabetes related conditions were estimated using attributable risk methodology. Costs were estimated in Brazilian currency, and then converted to international dollars (2014). Based on a national self-reported prevalence of 6.2%, the total cost of diabetes in 2014 was Int$ 15.67 billion, including Int$ 6.89 billion in direct medical costs (44%), Int$ 3.69 billion in non-medical costs (23.6%) and Int$ 5.07 billion in indirect costs (32.4%). Outpatient costs summed Int$ 6.62 billion and the costs of 314,334 hospitalizations attributed to diabetes and related conditions was Int$ 264.9 million. Most hospitalizations were due to cardiovascular diseases (47.9%), followed by diabetes itself (18%), and renal diseases (13.6%). Diet and transportation costs were estimated at Int$ 3.2 billion and Int$ 462.3 million, respectively. Our results showed a substantial economic burden of diabetes in Brazil, and most likely are underrated as they are based on an underestimated prevalence of diabetes. Healthcare policies aiming at diabetes prevention and control are urgently sought.

1 January 2019 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
MBMarcelo Imbroinise Bittencourt
Marcelo Imbroinise Bittencourt
SCSamária Ali Cader
Samária Ali Cader
DADenizar Vianna Araújo
Denizar Vianna Araújo
ASAna Luiza Ferreira Salles
Ana Luiza Ferreira Salles
FAFelipe Neves de Albuquerque
Felipe Neves de Albuquerque
RMRicardo Mourilhe-Rocha
Ricardo Mourilhe-Rocha
Hypertrophic cardiomyopathy (HCM) is associated with sudden death (SD). Myocardial fibrosis is reportedly correlated with SD. We performed a systematic review with meta-analysis, updating the risk markers (RMs) in HCM emphasizing myocardial fibrosis. We reviewed HCM studies that addressed severe arrhythmic outcomes and the certain RMs: SD family history, severe ventricular hypertrophy, unexplained syncope, non-sustained ventricular tachycardia (NSVT) on 24-hour Holter monitoring, abnormal blood pressure response to exercise (ABPRE), myocardial fibrosis and left ventricular outflow tract obstruction (LVOTO) in the MEDLINE, LILACS, and SciELO databases. We used relative risks (RRs) as an effect measure and random models for the analysis. The level of significance was set at p < 0.05. Twenty-one studies were selected (14,901 patients aged 45 ± 16 years; men, 62.8%). Myocardial fibrosis was the major RISK MARKER (RR, 3.43; 95% CI, 1.95-6.03). The other RMs, except for LVOTO, were also predictors: SD family history (RR, 1.75; 95% CI, 1.39-2.20), severe ventricular hypertrophy (RR, 1.86; 95% CI, 1.26-2.74), unexplained syncope (RR, 2.27; 95% CI, 1.69-3.07), NSVT (RR, 2.79; 95% CI, 2.29-3.41), and ABPRE (RR, 1.53; 95% CI, 1.12-2.08). We confirmed the association of myocardial fibrosis and other RMs with severe arrhythmic outcomes in HCM and emphasize the need for new prediction models in managing these patients.

1 June 2014 in Autoimmunity Reviews
Verified
Journal Article
Closed access
MAMirhelen Mendes de Abreu
Mirhelen Mendes de Abreu
VSVibeke Strand
Vibeke Strand
RLRoger Abramino Levy
Roger Abramino Levy
DADenizar Vianna Araujo
Denizar Vianna Araujo